Changes of Glucose in the Brains of Monkeys with MPTP Induced Parkins on’s Disease

LI Peng, ZHANG Zhu-jun, LI Yang, REN Hai-bo, ZHANG Shi-zhen, WANG Wei

Abstract

To examine the metabolic and behavioral changes of monkeys with MPTP induced Parkinson's disease. Methods Four healthy monkeys were injected with diluted MPTP solution continuously through peripheral veins. The behavioral changes of the monkeys were monitored with the Parkinson disease scale for monkeys.18FDG-PET-CT scans for the whole brain were obtained before and 3 months after the injection of MPTP. The pathological and glucose metabolic changes of the brains were examined. Results The animal model of Parkinson's disease was successfully established in all 4 monkeys, showing typical parkinsonian syndromes of bradykinesia, rigidity and hypokinesia. Changes in high nervous activities such as apathetic and less aggressive behaviors were also observed. Their scores of Parkinson disease scale exceeded 20. The parkinsonian syndromes were relieved after the administration of sinemet. The 18FDG-PET-CT scans showed significant glucose reduction after the MPTP injection within and outside of the basal ganglion area. Conclusion The metabolic changes of brains in the monkeys with Parkinson's disease are not limited to the basal ganglion area, which may be an important mechanism for the non-motor symptoms.

 

Keywords: Parkinson's disease, Monkey, MPTP, PET, Glucose metabolism


Full Text:

PDF


References


Samii A, Nutt JG, Ransom BR. Parkinson’s disease. The Lancet,2004 ;363(9423): 1783-1793.

Zhang ZX, Roman GC, Hong Z, et al. Parkinson’s disease in China:prevalence in Beijing. Xian and Shanghai. Lancet,2005; 365(9459):595-597.

Eslamboli A. Marmoset monkey model of Parkinson’s disease: which model, when and why? Brain Res Bull,2005 ;68(3); 140- 149.

Snow NA, Vingerhoets FJ, Langston JW. et al. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry,2000;68 (3) :313-316.

Nagai Y, Obayashi S, Ando К, et al. Progressist changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography. Synapse,2007;61 (10) :809-819.

Chen MK. Kuwabara H, Zhou Y, et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson ’ s disease. J Neurochem. 2008; 105 (1); 78-90.

Oiwa Y, Eberling JL, Nagy D« et al. Overlesioned hemiparkinsonian non human primate model; correlation between clinical, neurochemical and histochemical changes. Front Biosci,2003 ;8:al55-al66.

Brownell AL, Canales K, Chen YI, et al. Mapping of brain fuction after MPTP-induced neurotoxicity in a primate Parkinson1 s disease model. Neuroimage, 2003; 20 ( 2 ); 1064- 1075.

Baudrexel S. Witte T, Seifried C, et al. Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson’s disease. Neuroimage,2011 $55(4); 1728-1738. Haslinger B, Erhard P. Kampfe N, el al. Event-related functional magnetic resonance imaging in Parkinson’s disease before and after levodopa. Brain,2001; 124(3);558-566.

Drouot X. Oshino S, Jarraya B, et al. Functional recovery in a primate model of Parkinson ’ s disease following cortex stimulation. Neuron,2004 $44(5): 769-778.


Refbacks

  • There are currently no refbacks.